Licensing & Radiation Safety: The Regulatory Maze Behind Radiopharmaceutical Trials
Radiopharmaceutical clinical development is advancing quickly. More radioligand therapies are entering the clinic, and expectations around dose optimization and safety are becoming more defined. FDA’s recent guidance reflects this shift, with a clear focus on how dose and schedule are evaluated during development [1].
But before a single patient is enrolled, another reality shapes the pace of progress.
Radiopharmaceutical trials do not begin with site selection or patient recruitment alone. They begin with regulatory readiness across multiple systems that extend beyond a typical oncology study. For many sites, this is where timelines begin to stretch.
Regulatory Readiness Starts Before Trial Readiness
Radiopharmaceutical trials require coordination across several regulatory and institutional functions before a site can activate.
Depending on the study, this may include:
• Radioactive materials licensing
• Radiation safety approval
• Authorized user coverage
• Radiopharmacy handling and storage procedures
• Imaging workflow validation (PET/SPECT)
• Waste management and exposure monitoring
In the United States, the use of radioactive materials is governed through Nuclear Regulatory Commission or state level licensing frameworks, with defined roles for authorized users, radiation safety officers, and nuclear pharmacists [2].
These requirements reflect the dual nature of radiopharmaceuticals. They are developed as drugs, but they must also meet strict radiation safety standards. FDA guidance emphasizes understanding dose and exposure during development, while global frameworks define how radiation must be handled and controlled in clinical settings [1][3].
Each requirement is manageable on its own. Together, they create a system that is difficult to move through efficiently.
The Coordination Problem Behind the Compliance
The challenge is not simply regulatory burden. It is coordination.
Radiopharmaceutical trials sit at the intersection of clinical research, nuclear medicine, radiation safety, pharmacy operations, and imaging. Each group has its own processes, timelines, and review cycles. These workflows often run in parallel, but they are rarely integrated.
As a result:
• Licensing updates may lag behind protocol readiness
• Radiation safety reviews may require revisions
• Authorized personnel may not be immediately available
• Approval timelines may depend on fixed committee schedules
What appears to be a checklist quickly becomes a sequencing problem. And sequencing drives delay.
Why Even Experienced Sites Still Stall
Even experienced sites can face delays during activation.
A site may already have nuclear medicine infrastructure, prior radiopharmaceutical trial experience, and established radiation safety oversight. That helps, but it does not eliminate friction.
Each new study can introduce different radionuclides, dosing approaches, imaging requirements, or safety protocols. These changes often trigger new reviews or license updates. In some cases, specific procedures must be tied to authorized personnel listed on a license, which can further extend timelines [2].
Experience reduces uncertainty. It does not remove the need for re-approval.
The Hidden Role of Radiation Safety in Trial Timelines
Regulatory expectations are also evolving. FDA’s Project Optimus is placing greater emphasis on dose optimization in oncology drug development. In parallel, guidance for therapeutic radiopharmaceuticals reinforces the importance of understanding dose and treatment effects during clinical development.
This increases the need for reliable and consistent data collection across sites. It also raises the bar for what “trial-ready” truly means in practice [5].
Why This Matters for Sponsors
Radiation safety is one of the most important and often least visible drivers of activation timelines.
Before a study can begin, sites may need to evaluate exposure risks, approve handling procedures, confirm storage and transport requirements, and define monitoring protocols for staff. These steps are essential. Radiopharmaceuticals rely on controlled radiation delivery, which requires careful management of exposure.
Global frameworks reinforce this. The International Atomic Energy Agency outlines how radiation should be managed in clinical environments, while the European Medicines Agency emphasizes that clinical evaluation of radiopharmaceuticals must include radiation safety and dosimetry considerations [3][4].
These reviews are necessary, but they take time. Most radiation safety committees operate on fixed schedules, and approvals often depend on alignment across multiple departments.
Regulatory Complexity Is a Structural Bottleneck
These challenges point to a broader issue.
Regulatory readiness is not a simple administrative step. It is a structural bottleneck in radiopharmaceutical clinical development.
This becomes more pronounced as trials grow more complex. Many studies now include multiple imaging timepoints, dosimetry assessments, and greater emphasis on dose optimization. FDA guidance reinforces that dose understanding is central to development [1]. EMA has also signaled the need for more defined regulatory frameworks in this space [4].
Even early stage research illustrates how tightly controlled this field is. Under certain United States frameworks, such as RDRC pathways for basic research, strict limits are placed on radiation exposure for human subjects. While not representative of most therapeutic trials, these limits demonstrate how precisely radiopharmaceutical research is regulated [5].
For sites that are not structured around these requirements, the impact is clear. Longer activation timelines, reduced throughput, and increased operational burden.
Theragnostic Insight - Regulatory approval is not a single step. It is a system. Most systems are not built for speed.
What This Means for Sponsors
For sponsors, this changes how site readiness should be evaluated.
It is no longer enough to ask whether a site has nuclear medicine capabilities or prior experience. The more important questions are operational. How long do licensing updates take. How is radiation safety review scheduled. Are authorized personnel already in place. Can approvals run in parallel, or do they occur step by step.
Without this level of insight, activation timelines are often underestimated.
What This Means for You
Radiopharmaceutical trials bring a level of regulatory and operational complexity that traditional development models often underestimate.
The science may be ready. The protocol may be finalized. The site may appear qualified.
But until licensing, radiation safety, and institutional workflows are aligned, the study cannot begin.
At Theragnostic Insights, we work with development teams to evaluate these challenges early, map regulatory pathways, identify site specific risks, and align strategy with real world execution.
Because in radiopharmaceutical development, success depends not just on understanding the science. It depends on understanding what it takes to execute it.
Stay tuned for more in this mini-series: Clinical Capacity Crisis: The Hidden Bottleneck in Radiopharma Development.
In the coming weeks, we’ll continue exploring the clinical capacity crisis holding back radiopharmaceutical innovation; from regional access gaps to operational gridlock and infrastructure blind spots. Don’t miss the next post as we map out the road to a truly trial-capable ecosystem.
1. The Trial Site Gap: Why Radiopharmaceutical Innovation Is Hitting a Wall
2. Geography Is Destiny: The Clinical Access Gaps in Radiopharmaceutical Research
3. Operational Gridlock: Where Radiopharmaceutical Trials Break Down on Site
4. Beyond the Badge: Rethinking What “Trial-Ready” Really Means in Radiopharma
5. Infrastructure as Investment Strategy: Clinical Site Access and Radiopharma ROI
6. Built for What’s Next: Redefining Clinical Site Design for Theragnostic Trials
7. Speed as Strategy: How Site Scarcity Is Slowing Radiopharmaceutical Pipelines
8. One Roof, Many Bottlenecks: Why Fragmented Site Models Undermine RLT Trials
9. The Dosimetry Dilemma: Why Many Sites Aren’tReady for Radioligand Trials
10. Licensing & Radiation Safety: The Regulatory Maze Behind Radiopharmaceutical Trials
References:
[1] U.S. Food and Drug Administration, 2025. Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development. FDA.gov
[2] U.S. Nuclear Regulatory Commission, 2024. Medical Use Licensing and Part 35 Requirements. EMA.Europa.eu
[3] International Atomic Energy Agency, 2024–2025. Radiation Protection and Safety Standards. IAEA.org
[4] European Medicines Agency, 2024. Concept Paper on the Clinical Evaluation of Therapeutic Radiopharmaceuticals in Oncology. JNM.snmjournals.org
[5] Journal of Nuclear Medicine, 2025. FDA Reconsiders Rules Around Radiation Dosimetry for First-in-Human Radiopharmaceutical Studies. NRC.gov
